NCT07770087

Brief Summary

To evaluate, by standardized radiographic follow-up, whether locally delivered 1% metformin gel improves bone healing around immediately placed dental implants augmented with GBR.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2025

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

August 12, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 18, 2026

Completed
Last Updated

August 18, 2026

Status Verified

August 1, 2026

Enrollment Period

3 years

First QC Date

August 12, 2026

Last Update Submit

August 14, 2026

Conditions

Keywords

Metformin GelGuided Bone RegenerationImmediate Dental ImplantPosterior MaxillaPeri-implant Bone DensityCrestal Bone LossBone Regeneration

Outcome Measures

Primary Outcomes (1)

  • Peri-implant Bone Density

    Peri-implant bone density was assessed using cone-beam computed tomography (CBCT). Bone density was measured as the mean gray-scale value within a standardized region of interest adjacent to the dental implant. Changes in peri-implant bone density were compared between the metformin and control groups.

    Baseline (immediately after implant placement) , 6 months, and 12 months.

Secondary Outcomes (1)

  • Change in Crestal Bone Level

    Baseline (immediately after implant placement) and 6, 12 months.

Study Arms (2)

study group

EXPERIMENTAL

Participants received immediate dental implant placement with guided bone regeneration using an alloplastic bone graft and collagen membrane, with topical application of 1% metformin gel around the implant.

Drug: Metformin 1% Topical Gel

control group

EXPERIMENTAL

Participants received immediate dental implant placement with guided bone regeneration using the same alloplastic bone graft and collagen membrane protocol, without topical metformin gel.

Procedure: immediate Dental Implant Placement With Guided Bone Regeneration

Interventions

A 1% metformin gel was topically applied around the dental implant at the time of immediate implant placement. The intervention was used in conjunction with guided bone regeneration using an alloplastic bone graft and collagen membrane in the posterior maxillary region.

Also known as: Topical Metformin Gel
study group

Immediate dental implant placement was performed following atraumatic extraction in the posterior maxillary region. Guided bone regeneration was performed using an alloplastic bone graft and collagen membrane around the implant. This procedure was performed in both study groups; participants in the control group received this protocol without topical metformin gel.

Also known as: Immediate Implant Placement With GBR
control group

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \. All patients were free from any systemic diseases according to criteria of Cornell Medical Index and its modification(184).
  • \. Patent's age at least 18 years old. 3. Patients had remaining roots or badly decayed hopeless teeth indicated for extraction for immediate implant placement in the posterior maxilla region.
  • \. Extraction socket has sufficient bone quality and quantity amenable for implant length that is not less than 10 mm and of suitable diameter.
  • \. The implant recipient site should be free from any pathological conditions. 6. Patients with Good Oral Hygiene, and instructed for oral hygiene measures

You may not qualify if:

  • Patients with bad oral hygiene. 2. Uncontrolled systemic diseases that complicate bone healing. 3. Presence of any pathology in the implant site. 4. Heavy smokers, alcohol or drug abuse patients. 5. Patients with para functional habits such as bruxism and clenching. 6. Conditions that might lead to alteration of bone region as osteoporosis or Paget's disease.
  • \. Any medicines such as bisphosphonates or steroids that affect bone turn over.
  • \. History of chemotherapy or radiotherapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Faculty of Dental Medicine, Al-Azhar University, Assiut Branch

Asyut, Assiut Governorate, 71511, Egypt

Location

Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Al-Azhar University, Assiut Branch

Asyut, Egypt

Location

MeSH Terms

Interventions

MetforminGels

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic ChemicalsColloidsComplex MixturesDosage FormsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Postgraduate Researcher, Department of Oral and Maxillofacial Surgery

Study Record Dates

First Submitted

August 12, 2026

First Posted

August 18, 2026

Study Start

November 1, 2022

Primary Completion

November 15, 2025

Study Completion

December 15, 2025

Last Updated

August 18, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared because no data-sharing plan was included in the original study protocol or ethics approval, and participant confidentiality must be maintained.

Locations